Currently out of the existing stock ratings of Geoffrey Porges, 167 are a BUY (63.98%), 91 are a HOLD (34.87%), 3 are a SELL (1.15%).

Geoffrey Porges

Work Performance Price Targets & Ratings Chart

Analyst Geoffrey Porges, carries an average stock price target met ratio of 69.27% that have a potential upside of 28.82% achieved within 400 days. Previously, Geoffrey Porges worked at LEERINK.

Geoffrey Porges’s has documented 473 price targets and ratings displayed on 25 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on RCUS, Arcus Biosciences at 04-Aug-2022.

Wall Street Analyst Geoffrey Porges

Analyst best performing recommendations are on DOVA (DOVA PHARMACEUTICALS).
The best stock recommendation documented was for VRTX (VERTEX PHARMACEUTICALS) at 4/30/2020. The price target of $263 was fulfilled within 4 days with a profit of $11.8 (4.7%) receiving and performance score of 11.74.

Average potential price target upside

of $120.24 (26.04%) on REGN (REGENERON PHARMACEUTICALS).
of $50.78 (18.04%) on BIIB (BIOGEN).
of $49.91 (34.65%) on AMGN (AMGEN).

ABBV AbbVie ALXN Alexion Pharmaceuticals AMGN Amgen ASMB Assembly Biosciences AXLA Axcella Health BIIB Biogen CELG Celgene FGEN FibroGen GILD Gilead Sciences MOR MorphoSys AG ADR PAND Pandion Therapeutics PRNB Principia Biopharma RCUS Arcus Biosciences RDUS Schnitzer Steel Industries REGN Regeneron Pharmaceuticals TBPH Theravance Biopharma XLRN Acceleron Pharma EPZM Epizyme HALO Halozyme Therapeutics VRTX Vertex Pharmaceuticals PFE Pfizer SNY Sanofi ADR ZGNX Zogenix AZN AstraZeneca PLC ADR DOVA Dova Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Geoff Meacham (CITI)